Business
Exercise of Share Options by Director
Eco Animal Health Group plc announced that Chief Financial Officer Christopher Wilks exercised 4,309 nominal cost share options, which were satisfied by transferring existing ordinary shares from the Employee Benefit Trust, resulting in no new shares being issued. Following this transaction, Mr. Wilks' beneficial shareholding is 178,186 ordinary shares, representing approximately 0.26% of the issued share capital, while the total number of ordinary shares with voting rights remains at 67,759,671. Disclaimer*
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n18 December 2025\n\n \n \n \n \n \nECO Animal Health Group plc\n(\"ECO\" or the \"Company\")\n \nExercise of Share Options and Director/PDMR Shareholdings\n\nECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Christopher Wilks, Chief Financial Officer, has exercised 4,309 nominal cost share options granted under the Company's Deferred Bonus Share Options scheme (the \"Scheme\"). These share options were granted on 12 December 2022 as a deferral of one-third of Mr Wilks' bonus relating to the year ended 31 March 2022.\nThe exercise has been fully satisfied through the transfer of existing ordinary shares held by the ECO Animal Health Group Employee Benefit Trust (\"EBT\"). No new ordinary shares have been issued in connection with this transaction.\nAs a result of this transaction, Mr. Wilks' total beneficial shareholding in the Company is now 178,186 ordinary shares, representing approximately 0.26% of the Company's issued share capital (\"ISC\").\nTherefore, the total number of ordinary shares with voting rights in the Company remains at 67,759,671. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nThe notifications below, provided in accordance with the requirements of the UK Market Abuse Regulation, provide further details\n-Ends-\nFor further information please contact:\n\n\n\n\n\n\n\n\n \nECO Animal Health Group plc\nDavid Hallas (Chief Executive Officer)\nChristopher Wilks (Chief Financial Officer)\n \n\n\n\n020 8447 8899\n\n\n\n\nICR Healthcare (Financial PR)\nMary-Jane Elliott\nJessica Hodgson\n \n\n\n020 3709 5700\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Joint Broker)\nPhilip Davies\nSamed Ethemi\n \n\n\n020 7496 3000\n\n\n\n\nPanmure Liberum (Joint Broker)\nEmma Earl\nWill Goode\nMark Rogers\nRupert Dearden\n \n\n\n020 3100 2000 \n \n\n\n\n\nEquity Development\nHannah Crowe\nMatt Evans\n\n\n020 7065 2692\n\n\n\n\n\n\n\n \n\n\n\n...